295 related articles for article (PubMed ID: 25224659)
1. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
4. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
Wang Y; He L; Cheng Y
Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
[TBL] [Abstract][Full Text] [Related]
5. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.
Kim H; Seo S; Kim K; Park YH; An M; Baik H; Choi C; Oh S
World J Surg Oncol; 2019 Jul; 17(1):122. PubMed ID: 31296222
[TBL] [Abstract][Full Text] [Related]
8. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
9. HER2 in resected gastric cancer: Is there prognostic value?
Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB; Maithel SK
J Surg Oncol; 2014 Feb; 109(2):61-6. PubMed ID: 24122802
[TBL] [Abstract][Full Text] [Related]
10. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
Fusco N; Rocco EG; Del Conte C; Pellegrini C; Bulfamante G; Di Nuovo F; Romagnoli S; Bosari S
Mod Pathol; 2013 Jun; 26(6):816-24. PubMed ID: 23348899
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
[TBL] [Abstract][Full Text] [Related]
12. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
15. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
16. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
17. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
18. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
19. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
[TBL] [Abstract][Full Text] [Related]
20. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
